Product Description
Docetaxel injection is used to treat advanced or metastatic (cancer that has spread) breast cancer in patients who have previously received other cancer medicines that did not work well. It is also used together with other medicines (eg, cyclophosphamide, doxorubicin) to treat node-positive breast cancer that can be removed by surgery. Docetaxel belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by docetaxel, other unwanted effects will also occur. (Sourced from: https://www.mayoclinic.org/drugs-supplements/docetaxel-intravenous-route/side-effects/drg-20068305?p=1)
Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Breast Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Prostate Cancer | Small Cell Lung Cancer | Oncology Unspecified
Known Adverse Events: Dysgeusia | Pain Unspecified | Alopecia | Mucositis | Anemia | Thrombocytopenia | Neutropenia | Cross Infection | Myalgia | Dyspnea | Anorexia | Asthenia | Constipation | Diarrhea | Febrile Neutropenia
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Jordan, Korea, Lebanon, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 173
Highest Development Phases
Phase 3: Adenocarcinoma|Breast Cancer|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Neutropenia|Non-Small-Cell Lung Cancer|Other|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Prostate Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer
Phase 2: Anal Cancer|Anus Cancer|Biliary Tract Cancer|Bladder Cancer|Brain Cancer|Carcinoma, Merkel Cell|Cervical Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Hepatocellular Carcinoma|Liver Cancer|Melanoma|Menopause|Muscle Cancer|Nasopharyngeal Cancer|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Renal Cell Carcinoma|Sarcoma|Sarcoma, Ewing|Uterine Cancer
Phase 1: Epilepsy|Healthy Volunteers|Lung Cancer|Muscle Spasticity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PEACE6-Poor Responders | P3 |
Recruiting |
Prostate Cancer |
2033-02-01 |
|
| STAMPEDE2 | P3 |
Recruiting |
Prostate Cancer |
2031-04-01 |
|
| TRIPLE-SWITCH | P3 |
Not yet recruiting |
Adenocarcinoma|Prostate Cancer |
2031-03-14 |
|
| STAMPEDE | P3 |
Unknown status |
Prostate Cancer |
2030-12-04 |